S tatin (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) is a lipid-lowering agent that also has multiple cholesterol-independent pleiotropic effects, including the improvement of endothelial function, inhibition of inflammation and thrombosis, promotion of angiogenesis and neuroprotection, and stabilization of atherosclerotic plaques.
Stroke
October 2017
Study Subjects
We included patients who were ≥20 years old with acute ischemic stroke, defined as hospitalization (admission or emergency department visit) with a primary diagnosis of ischemic stroke (I63) between 2002 and 2012. The index date was the starting date of the first hospitalization for the acute ischemic stroke. Inclusion and exclusion criteria are explained in Figure 1 and in the online-only Data Supplement.
Clinical Outcome
The primary outcome was a composite of recurrent stroke, myocardial infarction (MI), and all-cause death, whichever occurred earliest.
Patients were diagnosed with recurrent stroke if they were rehospitalized with a primary diagnosis of I60-63 (ischemic stroke, I63; hemorrhagic stroke, I60-62) and underwent brain computed tomography or MRI at the hospital visit. MI was defined as hospitalization with a primary diagnosis of I21. The diagnostic accuracy of I60-I63 for stroke in the NHIS has been reported as >80% in validation studies. 11, 12 The accuracy of I21 for MI in the NHIS has been reported as 73% to 93%. 13, 14 
Assessment of Statin Use After Ischemic Stroke
We collected data from the prescription records (type, dosage, duration, and date) of statin (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin) in NHIS-NSC. Adherence to statin therapy was estimated by calculating the proportion of days covered (PDC) for a period of 1 year after acute ischemic stroke. 15 For the calculation of the PDC, the numerator was the number of days covered by any statin prescription during 1 year after the index date, and the denominator was 365. Based on the PDC by statin, the patients were classified into the following groups: no statin, poor adherence (PDC <40%), intermediate adherence (PDC 40%-80%), or good adherence (PDC >80%). A cutoff of 80% for the PDC is considered reasonable for good drug adherence. 16 Each patient in the good adherence group was further assigned to lowintensity, moderate-intensity, or high-intensity subgroups according to the intensity of the most frequently used statin (statin type and dose per day). The classification of statin intensity was based on the 2013 American College of Cardiology/American Heart Association Guidelines on the Treatment of Blood Cholesterol. 17 The data on the statin types and doses for classification are summarized in Table I in the online-only Data Supplement. Previous statin use was defined as any use of statin during the 6-month period before the index stroke.
Covariates
The presence of hypertension, diabetes mellitus, atrial fibrillation, prior MI, and use of thrombolysis were defined by the diagnostic code and procedure code in the NHIS-NSC. We collected data for sex, age, household income, type of hospitals, and years of index stroke. As markers for other medical treatment, adherence to oral antithrombotics (antiplatelet or anticoagulant) and antihypertensive medications (only in patients with hypertension) were analyzed by calculating PDC for a period of 1 year after acute ischemic stroke (poor adherence: <40%, intermediate adherence: 40%-80%, good adherence: >80%).
Statistical Analyses
The data manipulation and statistical analyses were performed with PostgreSQL, version 9.6.1 (The PostgreSQL Global Development Group; https://www.postgresql.org/), and R software, version 3.3.3 (The R Foundation for Statistical Computing, Vienna, Austria; http:// www.R-project.org/). A 2-sided P<0.05 was considered to be statistically significant.
Further information for the covariates and statistical method are explained in the online-only Data Supplement.
Results
This study included 8001 patients with acute ischemic stroke according to the inclusion and exclusion criteria (Figure 1 
Relationships of Patient Characteristics and Pattern of Statin Use
When we compared patients who received statin to those who did not (Table 1) , the no statin group was more likely to be old, hospitalized in a clinic, with low household income, and have an early index-stroke year. In contrast, hypertension, diabetes mellitus, atrial fibrillation, prior MI, use of thrombolysis, good adherence to antithrombotics, and good adherence to antihypertensive medication were more frequent in those who received statin. Among the 3624 patients who received statin, an increase in statin adherence was associated with male sex, diabetes mellitus, use of thrombolysis, high household income, hospitalization in a general hospital for an index stroke in the late study period, good adherence to antithrombotics, and good adherence to antihypertensive medication (Table 1) . When we compared characteristics according to statin intensity in the 1712 patients with good adherence (Table III in the online-only Data Supplement), high-intensity statin was significantly associated with low household income, late index-stroke year, and good adherence to antithrombotic medication but not with other risk factors. 
Outcome According to Statin Adherence
During 4.69±2.72 years (mean±SD) of follow-up period, a primary outcome occurred in 2284 patients (28.5%; including 698 recurrent ischemic stroke, 107 hemorrhagic stroke, 96 MI, and 1383 all-cause death; considering only the first event per patient). The Kaplan-Meier curve for event-free survival demonstrated a significant association between increase in statin adherence and lower risk of adverse events (Figure 2A ; P<0.001). In the multivariate Cox regression model, there was an inversed relationship between adherence to statin and risk for adverse events ( Table 2) 
Outcome According to Statin Intensity
To evaluate the effects of stain intensity, we performed subgroup analysis for the patients with good adherence (n=1712), who were subdivided into low-intensity, moderate-intensity, and high-intensity subgroups. The Kaplan-Meier curve for the subgroups showed significant dose-response relationship between the statin intensity and event-free survival ( Figure 2B ; P for trend=0.028). In the multivariate Cox model for the subgroups with good adherence, adjusted hazard ratios (95% confidence interval) were 0.48 (0.24-0.96) for those with high-intensity statin and 0.77 (0.55-1.09) for those A B Figure 2 . Kaplan-Meier curves of event-free survival according to statin therapy after acute ischemic stroke A, An increase of adherence to statin therapy is significantly associated with lower risk of adverse events (P for trend<0.001). B, In the subgroups with good adherence to statin (n=1712), there is dose-response relationship between statin intensity and event-free survival (P for trend=0.028). with moderate-intensity statin compared with those with the low-intensity.
Secondary Outcome
We constructed individual Cox regression models for each of the following events of interest: recurrent ischemic stroke (n=713), hemorrhagic stroke (n=127), MI (n=107), and allcause mortality (n=1740). In the secondary outcome analyses, the preventive benefit of statin therapy was significant for reducing all-cause mortality (Figure 3) . The risk of hemorrhagic stroke was not increased with the good adherence to statin and high intensity of statin.
Additional Analysis
To evaluate the effects of statin by risk factors, we performed subgroup analyses by sex; age; presence of hypertension, diabetes mellitus, atrial fibrillation, prior MI; household income; year of index stroke; prior statin use; adherence to antithrombotics; and adherence to antihypertensive medications (Table IV in the online-only Data Supplement). Across the subgroups, the preventive effects of adherent statin therapy were consistent. We also performed analyses using the PDC by statin for a period of 3 and 6 months after acute ischemic stroke (Figures I and II in the online-only Data Supplement). The findings are compatible with those from the primary analysis with PDC for a period of 1 year.
Discussion
This cohort study of acute ischemic stroke demonstrated that adherent statin therapy had substantial long-term preventive effects compared with no or nonadherent statin therapy. Furthermore, an inverse dose-response relationship was observed between statin intensity and the risk of adverse events after stroke. The SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) is a landmark randomized trial that established that the daily use of highintensity statin (80 mg atorvastatin) in patients who had recent stroke or transient ischemic attack without cardioembolic Figure 3 . Risk for the primary and secondary outcomes after acute ischemic stroke according to statin therapy. Data are derived from multivariate Cox regression analyses adjusted for the same covariates listed in Table 2 . For calculating hazard ratio, the reference is no statin group. Composite outcome is defined as ischemic stroke, hemorrhagic stroke, myocardial infarction, and all-cause mortality. CI indicates confidence interval; and UD, undetermined because of no outcome event in the subgroup.
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sources significantly reduced major cardiovascular events by 20% compared with placebo. 8 However, the SPARCL trial did not include a group treated with low or conventional dose of statin. Unlike the established evidence for the dosedependent preventive effects of statin after coronary artery disease, there were only a few inconsistent reports for the effect of statin intensity in acute stroke. The North Dublin Population Stroke Study, a prospective observation study of 448 patients with ischemic stroke, showed a dose-response relationship between the dose of atorvastatin and favorable outcomes, including early functional outcome and 1-year poststroke mortality. 18 In a study that evaluated the 1-year poststroke mortality of 12 689 patients according to the dose of statin that was used before and during the hospitalization, the risk was lower in the high-dose statin group than in the low-to moderate-dose statin groups. 19 A recent prospective study in stroke patients with large artery atherosclerosis demonstrated a dose-dependent association between dose of statin pretreatment and microembolic signals on transcranial Doppler monitoring. 20 In contrast, the PROSPER study (Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research) of Medicare claims data reported that statin therapy at discharge had a lower hazard of major adverse cardiovascular events and all-cause mortality, while statin intensity was not associated with clinical outcomes. 21 The discrepancy between the studies might be partly ascribed to the nonpersistency of statin therapy; early withdrawal or discontinuation of statin, which is common after acute stroke, could even be harmful. 9 Our study evaluated both the intensity and adherence of statin therapy after acute stroke. Adverse events were significantly reduced with good adherence to the statin therapy, and the events were further reduced with high-intensity statin. These findings support the current American Stroke Association guidelines for the secondary prevention of stroke that recommend intensive lipid-lowering statin therapy for patients who had ischemic stroke or transient ischemic attack that were presumed to be of atherosclerotic origin. 22 In addition, we found that the preventive benefits of statin did not differ according to the presence of atrial fibrillation, which is the most common cause of cardioembolic stroke. This finding was consistent with those of a previous study that showed a protective effect of statin in patients who had cardioembolic stroke. 23 The early use of intensive statin therapy might be beneficial for all patients who had acute stroke regardless of the underlying mechanism. 24, 25 One concern for early statin therapy in acute ischemic stroke is whether the use of statin increases the risk of intracerebral hemorrhage. A post hoc analysis of the SPARCL trial showed an increase in the incidence of hemorrhagic stroke with 80 mg of atorvastatin. 8 Observational studies have suggested that the risk of hemorrhagic stroke is increased with the use of statin before or during admission. 26 However, the current study did not show a significant association between the risk of hemorrhagic stroke and statin use or the intensity of statin. Consistent with the findings of our study, meta-analyses and retrospective propensity-matched cohort studies have shown that there was no significant association between statin therapy and the risk of hemorrhagic stroke. 27, 28 A recent randomized trial of patients who had acute ischemic stroke demonstrated that hemorrhagic transformation on gradient-recalled echo MRI was reduced with 20 mg of rosuvastatin compared with placebo. 29 Another real-world data in Taiwan have shown that statin therapy in patients who had acute ischemic stroke did not increase the risk of hemorrhagic stroke. 30 In this study of real-world data for patients in South Korea who had acute ischemic stroke between 2002 and 2012, more than half did not receive statin. Although the proportion of patients treated with statin has consistently increased from 18.3% in 2002 to 63.1% in 2012, suboptimal adherence was frequent, and the proportion of patients receiving high-intensity statin was still low. The underuse of statin has been reported in the real-world data of acute stroke as well as MI. [30] [31] [32] [33] The available data consistently report worse clinical outcomes without statin or with poor adherence to statin after acute MI and ischemic stroke. 15, 30 Achieving good adherence to statin was significantly associated with a lower risk for secondary cardiovascular events. 31 Not limited to statin, clinicians should concern that nonadherent use of cardiovascular preventive medications, including antihypertensive or antithrombotic drugs, is a major risk factor contributing to a significant portion of the residual cardiovascular risk but often unrecognized. In various disease populations, nonadherence to the evidencebased medications is frequent and consistently associated with worse clinical outcomes. 15, 16, 34, 35 The suboptimal use of preventive medications in the practice might be an important clinical target to improve the quality of care and reduce the residual risk.
This study had both strengths and limitations. This study was based on the real-world data of a nationwide health insurance claim database. We collected the prescription data on statin and long-term outcomes for >10 years for >8000 patients who had acute ischemic stroke. However, there are potential limitations of the retrospective observational design. Because NHIS-NSC consists of random selection of 2.2% of the Korean population, selection bias is possible. 10 The NHIS-NSC did not include information on possible confounding factors, such as initial stroke severity, radiological results, laboratory findings, and the etiologic mechanism of stroke. We could not perform subgroup analysis according to the stroke subtype. Even with prior validation studies, patient's inclusion and outcome detection based on International Statistical Classification of Diseases, Tenth Revision code might have limited accuracy. We could not capture patients who experienced adverse events without hospitalization. Nevertheless, improved survival, captured by national health insurance system, suggested the significant benefit of aggressive statin therapy after acute ischemic stroke. We measured drug adherence based on prescription records in NHIS-NSC, from which it was not certain the patients actually took the prescribed drug. Besides statin therapy, the recent improvements in stroke management and risk factor control might have contributed to the findings of better clinical outcomes. Because of these limitations, additional studies on the effects of statin intensity and strategies to increase statin adherence after acute stroke are needed.
Conclusions
This study showed that the adherent use of high-intensity statin had substantial long-term benefits on the prevention of adverse events after acute ischemic stroke without an increased risk of hemorrhagic stroke. There are needs for interventions and encouragements for the use and continuation of high-intensity statin in acute ischemic stroke.
